Department of Obstetrics and Gynecology, Antalya Training and Research Hospital, Antalya, Turkey.
Department of Obstetrics and Gynecology, Aksaray Training and Research Hospital, Antalya, Turkey.
Surg Infect (Larchmt). 2024 Nov;25(9):668-673. doi: 10.1089/sur.2024.075. Epub 2024 Aug 13.
This study investigates the practicability of serum kallistatin as a biomarker in the diagnosis of tubo-ovarian abscess (TOA) because C-reactive protein (CRP) is insufficiently specific for diagnosis. Thirty patients (control group) who presented for elective gynecological surgeries and 30 who were hospitalized due to TOA (study group) at the Antalya Training and Research Hospital Gynecology Clinic, Türkiye, between January 1 and December 31, 2022, were included in the study. Blood samples were collected for the calculation of complete blood count, biochemistry, CRP, and serum kallistatin values, and the results were recorded in a database. Although no significant differences were observed between the control and study groups in terms of age or body mass index, significant differences were observed in terms of marital status, number of pregnancies, parity number, intrauterine device history, and previous surgical history (p > 0.05). Serum hemoglobin levels (12.61 ± 1.30 vs. 11.47 ± 1.77; p = 0.008), white blood cell (7.9 [6.15 ± 9.7] vs. 17.0 [11.6-19.6]; p < 0.001), neutrophil (4.6 [3.6-6.12] vs. 13.6 [9.25-16.1]; p < 0.001), lymphocyte (2.51 ± 0.71 vs. 2.33 ± 0.69; p = 0.307), and platelet counts (285.63 ± 78.0 vs. 407.03 ± 131.96; p < 0.001), neutrophil-lymphocyte ratio (2.11 ± 0.93 vs. 6.18 ± 2.20; p < 0.001), neutrophil-lymphocyte ratio (123.16 ± 52.63 vs. 184.39 ± 63.90; p < 0.001), hs-CRP (1.20 [5.55-1.92] vs. 240 [138.25-291.0]; p < 0.001), kallistatin (7.18 ± 3.15 vs. 3.83 ± 3.69; p = 0.006), and urine leukocyte values (1 [0.75-3] vs. 3 [1-6.5]; p = 0.038) also differed significantly between the control and study groups. The study findings show that serum kallistatin levels can be used as a biomarker in the diagnosis of TOA. Further studies involving more participants are now needed to test the accuracy of our results.
本研究旨在探讨血清激肽释放酶抑制剂(kallistatin)作为诊断输卵管卵巢脓肿(TOA)生物标志物的实用性,因为 C 反应蛋白(CRP)的诊断特异性不足。2022 年 1 月 1 日至 12 月 31 日期间,土耳其安塔利亚培训与研究医院妇科诊所纳入了 30 名(对照组)因择期妇科手术就诊的患者和 30 名(研究组)因 TOA 住院的患者。采集血样以计算全血细胞计数、生化、CRP 和血清激肽释放酶抑制剂值,并将结果记录在数据库中。虽然对照组和研究组在年龄或体重指数方面无显著差异,但在婚姻状况、妊娠次数、产次、宫内节育器史和既往手术史方面存在显著差异(p > 0.05)。血清血红蛋白水平(12.61 ± 1.30 与 11.47 ± 1.77;p = 0.008)、白细胞(7.9 [6.15 ± 9.7] 与 17.0 [11.6-19.6];p < 0.001)、中性粒细胞(4.6 [3.6-6.12] 与 13.6 [9.25-16.1];p < 0.001)、淋巴细胞(2.51 ± 0.71 与 2.33 ± 0.69;p = 0.307)和血小板计数(285.63 ± 78.0 与 407.03 ± 131.96;p < 0.001)、中性粒细胞-淋巴细胞比值(2.11 ± 0.93 与 6.18 ± 2.20;p < 0.001)、超敏 C 反应蛋白(hs-CRP)(1.20 [5.55-1.92] 与 240 [138.25-291.0];p < 0.001)、激肽释放酶抑制剂(7.18 ± 3.15 与 3.83 ± 3.69;p = 0.006)和尿白细胞值(1 [0.75-3] 与 3 [1-6.5];p = 0.038)在对照组和研究组之间也存在显著差异。本研究结果表明,血清激肽释放酶抑制剂水平可作为诊断 TOA 的生物标志物。目前需要更多参与者参与的进一步研究来检验我们结果的准确性。